Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain ...

Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total ...

These abstracts summarize Versamune ® HPV (PDS0101) studies to be presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois. Kirk Shepard, M.D., ...

Labroots’ virtual events enable individuals worldwide to connect and engage in groundbreaking scientific research from your ...

Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at ...

Finance Income, net was $1.0 million for the three months ended March 31, 2025, compared to $0.7 million in the same period ...

Treatment practices in the U.S. show approximately 75% of diagnosed pulmonary sarcoidosis patients require treatment with ...

Awarded earlier this year, the $44M Birmingham Biotechnology Hub grant was set to support the growth of Alabama's ...

FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics ...

Operator: Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call. All participants are in a listen-only mode.